BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
The information in this Current Report on Form 8-K (this “Current Report”) is being furnished to Item 2.02 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement to the Securities Act of 1933, as amended.
On April 3, 2018, Bio-Path Holdings, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2017. Additional information is included in the Company’s press release. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press Release dated April 3, 2018|
BIO-PATH HOLDINGS INC ExhibitEX-99.1 2 tv490214_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BIO-PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULTS Conference Call to be Held Today at 8:30 A.M. ET HOUSTON—April 3,…To view the full exhibit click
About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.